Pharma Mar Sa Stock Annual Yield

PHM Stock  EUR 75.60  2.10  2.86%   
Pharma Mar SA fundamentals help investors to digest information that contributes to Pharma Mar's financial success or failures. It also enables traders to predict the movement of Pharma Stock. The fundamental analysis module provides a way to measure Pharma Mar's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharma Mar stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Pharma Mar SA Company Annual Yield Analysis

Pharma Mar's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.

Yield

 = 

Income from Security

Current Share Price

More About Annual Yield | All Equity Analysis

Current Pharma Mar Annual Yield

    
  0.01 %  
Most of Pharma Mar's fundamental indicators, such as Annual Yield, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharma Mar SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
Competition

In accordance with the recently published financial statements, Pharma Mar SA has an Annual Yield of 0.0102%. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The annual yield for all Spain stocks is notably lower than that of the firm.

Did you try this?

Run Portfolio Center Now

   

Portfolio Center

All portfolio management and optimization tools to improve performance of your portfolios
All  Next Launch Module

Pharma Fundamentals

About Pharma Mar Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pharma Mar SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharma Mar using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharma Mar SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Pharma Stock

Pharma Mar financial ratios help investors to determine whether Pharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharma with respect to the benefits of owning Pharma Mar security.